<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782834</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107DUS05T</org_study_id>
    <nct_id>NCT00782834</nct_id>
  </id_info>
  <brief_title>Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)</brief_title>
  <acronym>07060</acronym>
  <official_title>Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of Nilotinib for patients with advanced GIST that cannot be&#xD;
      surgically removed. Patients are candidates for the study if their tumors have progressed on&#xD;
      imatinib and sunitinib or if they were intolerant to these drugs. Patients may have received&#xD;
      other investigational therapies as well. We are testing the benefit of nilotinib in advanced&#xD;
      GIST looking at the length of time disease is controlled as well as the response of the&#xD;
      disease to the drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nilotinib is an oral drug. The dose is 400 mg twice daily&#xD;
&#xD;
      Patients are evaluated every 8 weeks for disease response. Blood work is assessed for safety&#xD;
      initially weekly, then every 4 weeks. Physical exams are performed initially weekly and then&#xD;
      decreased to every 4 weeks after the first month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stopped early for futility, unable to meet accrual goals&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants that demonstrate progression free survival at 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>1year</time_frame>
    <description>Response rate of nilotinib by RECIST criteria evaluated every 2 months for the first 6 months then every 3 months for the duration of treatment period.</description>
  </primary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>400 mg orally twice daily until disease progression, intolerability or withdrawal of consent</description>
    <other_name>Tasigna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed GIST&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=&#xD;
             20 millimeters (mm) with conventional techniques or as &gt;= 10 mm with spiral CT scan.&#xD;
&#xD;
          -  Patients may have received prior chemotherapy or radiation therapy. Patients must have&#xD;
             recovered from any prior therapy and at least 4 weeks (6 weeks for nitrosoureas or&#xD;
             mitomycin C; 2 weeks for limited field palliative radiation) must have elapsed since&#xD;
             prior treatment.&#xD;
&#xD;
          -  Patients must have received and progressed on imatinib and sunitinib. Except for&#xD;
             nilotinib, patients may have received additional tyrosine kinase inhibitors or&#xD;
             additional targeted therapies.&#xD;
&#xD;
          -  Age &gt;= 18 years.&#xD;
&#xD;
          -  Life expectancy of greater than 12 weeks.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  absolute neutrophil count &gt;= 1,500/mcL&#xD;
&#xD;
               -  platelets &gt;= 100,000/mcL&#xD;
&#xD;
               -  total bilirubin &lt;= 1.5 times Upper Limits of Normal (ULN)&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt;= 2.5 X ULN OR &lt;= 5.0 X ULN if considered due to tumor&#xD;
&#xD;
               -  Potassium, magnesium normal or corrected to normal limits prior to initiating&#xD;
                  drug&#xD;
&#xD;
               -  Calcium, phosphorus normal or corrected to normal limits prior to initiating drug&#xD;
&#xD;
               -  creatinine within normal institutional limits&#xD;
&#xD;
               -  creatinine clearance 24 hour creatinine clearance &gt;= 50 mL/min (calculation by&#xD;
                  cockroft formula is acceptable)&#xD;
&#xD;
          -  The effects of Nilotinib on the developing human fetus at the recommended therapeutic&#xD;
             dose are unknown. Men or women of childbearing potential (WOCBP), to include female&#xD;
             partners of heterosexual or bisexual patients, must agree to use an effective method&#xD;
             of contraception during the study and for up to three months following termination of&#xD;
             the study. Post menopausal women must be amenorrheic for at least 12 months to be&#xD;
             considered of non-childbearing potential.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents within 4 weeks.&#xD;
&#xD;
          -  Prior or concomitant malignancies (with a relapse in the last 5 years or requiring&#xD;
             active treatment) other than GIST and with the exception of previous or concomitant&#xD;
             basal cell skin cancer, previous cervical carcinoma in situ&#xD;
&#xD;
          -  Impaired cardiac function at baseline, including any one of the following:&#xD;
&#xD;
               -  Left Ventricular Ejection Fraction (LVEF)&lt; 45% or below the institutional Lower&#xD;
                  Limits of Normal (LLN) range (whichever is higher)&#xD;
&#xD;
               -  Complete left bundle branch block&#xD;
&#xD;
               -  Use of a ventricular paced cardiac pacemaker&#xD;
&#xD;
               -  Congenital long QT syndrome or family history of long QT syndrome&#xD;
&#xD;
               -  History of or presence of significant ventricular or atrial tachyarrhythmias&#xD;
&#xD;
               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)&#xD;
&#xD;
               -  QTc &gt; 450 msec on screening ECG (using the QTcF formula). If QTc &gt; 450 msec and&#xD;
                  electrolytes are not within normal ranges (electrolytes should be corrected and&#xD;
                  then the patient rescreened for QTc.&#xD;
&#xD;
               -  Right bundle branch block plus left anterior hemiblock, bifascicular block&#xD;
&#xD;
               -  Myocardial infarction within 12 months prior to Visit 1&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., unstable angina, congestive&#xD;
                  heart failure or uncontrolled hypertension)&#xD;
&#xD;
          -  Patients with severe and/or uncontrolled concurrent medical disease that in the&#xD;
             opinion of the investigator could cause unacceptable safety risks or compromise&#xD;
             compliance with the protocol e.g. impairment of gastrointestinal (GI) function, or GI&#xD;
             disease that may significantly alter the absorption of the study drugs, uncontrolled&#xD;
             diabetes&#xD;
&#xD;
          -  Use of therapeutic coumarin derivatives (i.e. warfarin, acenoucumarol, phenprocoumon)&#xD;
&#xD;
          -  Use of any medications that prolong the QT interval and CYP3A4 inhibitors if the&#xD;
             treatment cannot be either safely discontinued or switched to a different medication&#xD;
             prior to starting study drug administration. Please see&#xD;
             http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm for a&#xD;
             comprehensive list of agents that prolong the QT interval as well as&#xD;
&#xD;
          -  Patients who have undergone major surgery &lt;= 2 weeks prior to Visit 1 or who have not&#xD;
             recovered from side effects of such surgery&#xD;
&#xD;
          -  A history of noncompliance to medical regimens or inability or unwillingness to return&#xD;
             for scheduled visits, patients who are pregnant or breast feeding, and patients&#xD;
             unwilling or unable to comply with the requirements for the protocol.&#xD;
&#xD;
          -  Patient has known chronic liver disease (i.e., chronic active hepatitis, and&#xD;
             cirrhosis).&#xD;
&#xD;
          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret von Mehren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>December 17, 2010</results_first_submitted>
  <results_first_submitted_qc>August 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2011</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>Nilotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were accrued between 7/03/2008 and 9/24/2009 at Fox Chase Cancer Center outpatient medical oncology clinics.</recruitment_details>
      <pre_assignment_details>Advanced GIST with measurable disease; previously treated with at least imatinib and sunitinib; a 5-day washout from prior tyrosine kinase inhibitor therapy. Normal cardiac function with LVEF 45% or &gt;, no history of significant heart disease,arrhythmias,congenital long QT sydrome, heart block, MI within 12 mos of visit 1 or unstable angina, CHF</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib Arm</title>
          <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screened Patients</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">1 pt ineligible d/t arrhythmia</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>fibrous tumor not GIST</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Screened:&#xD;
Started: 15 patients Completed: 14 patients Comments: 1 patient deemed ineligible due to arrhythmia.&#xD;
Treatment Phase:&#xD;
Started: 14 patients Completed: 13 patients Comments: 1 patient on extensive pathology review was found to have a solitary fibrous tumor, not GIST.</population>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib Arm</title>
          <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9" lower_limit="54" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="68" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Site of Cancer</title>
          <description>Stomach 6; Small bowel 5; Colon 1; Rectum 1</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Bowel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Tyrosine Kinase Inhibitor (TKI)</title>
          <description>Imatinib (IM) + Sunitinib (SU); Imatinib + Sunitinib + Nasatinib (NA); Imatinib +Sunitinib + Radiotherapy (RT) + Chemotherapy (CT)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IM and SU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IM, SU and NA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IM, SU, RT and CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Rate at 6 Months</title>
        <description>Number of participants that demonstrate progression free survival at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib Arm</title>
            <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Rate at 6 Months</title>
          <description>Number of participants that demonstrate progression free survival at 6 months</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Response rate of nilotinib by RECIST criteria evaluated every 2 months for the first 6 months then every 3 months for the duration of treatment period.</description>
        <time_frame>1year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib Arm</title>
            <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Response rate of nilotinib by RECIST criteria evaluated every 2 months for the first 6 months then every 3 months for the duration of treatment period.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib Arm</title>
          <description>All patients treated with nilotinib 400 mg BID orally daily; 4 weeks = one cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain associated with constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea vomiting weakness followed by death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Severe abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Profound weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status dec pulse ox</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute azotemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GI Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hoarseness voice changes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alk Phos</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>SGOT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study failed to meet its accrual goals. Study terminated prior to accruing 17 subjects due to futility of meeting endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret von Mehren, M.D., Director of Sarcoma Oncology</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-728-2814</phone>
      <email>margaret.vonMehren@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

